Word is it was Baker Bros, and if so it doesn't amount to that big of a bet for them (they already had a position, not sure how big) and still useful for SMMT.
Summit Raises $200 Million; Also Expands License Territories for Ivonescimab $200 Million in Net Proceeds Raised at Premium to Previous Closing Price
In Separate Transaction, Summit Expanded License Territories for Ivonescimab in Deal with Akeso to Include Latin America, Middle East, and Africa
Expansion Is in Addition to Existing License Territories of US, Canada, Europe, and Japan
Conference Call to be Held at 8:00am ET on Monday, June 3, 2024
Miami, Florida, June 3, 2024 – Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that the Company received and accepted an unsolicited offer from an institutional investor to purchase 22,222,222 shares of the Company’s common stock at $9.00 per share, a premium to the closing price on Friday, May, 31, 2024, for aggregate gross proceeds to the Company of approximately $200.0 million.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.